公开(公告)号：US20050119288A1

公开(公告)日：2005-06-02

申请号：US10919831

申请日：2004-08-17

Applicant: Samit Bhattacharya ,  Richard Connell ,  Jitesh Jani ,  James Moyer ,  Dennis Noe ,  Stefanus Steyn

Inventor： Samit Bhattacharya ,  Richard Connell ,  Jitesh Jani ,  James Moyer ,  Dennis Noe ,  Stefanus Steyn

IPC: A61K31/00 ,  A61K31/506 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/00 ,  A61K31/506 ,  A61K31/517 ,  A61K2300/00

Abstract: The invention is directed to methods for the a method for treating overexpression of the erbB2 in a mammal in need of treatment by administering to the mammal a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 hours, administering to the mammal from one to six therapeutically effective amounts of the same or different inhibitor of the erbB2 receptor. The invention is also directed to a slow daily infusion of the erbB2 inhibitor. The overexpression of the erbB2 receptor can result in abnormal cell growth and lead to cancer. By the methods of the invention, the efficacy and safety of the inhibitors is increased. The invention is also directed to kits for facilitating the dose administration method of the invention.

Abstract translation: 本发明涉及用于治疗需要治疗的哺乳动物中erbB2的过度表达的方法，其通过向哺乳动物施用治疗有效量的第一种erbB2受体抑制剂，然后在间隔小于24 小时，向哺乳动物施用1至6个治疗有效量的相同或不同的erbB2受体抑制剂。 本发明还涉及缓慢的每日输注erbB2抑制剂。 erbB2受体的过度表达可导致细胞生长异常并导致癌症。 通过本发明的方法，抑制剂的功效和安全性增加。 本发明还涉及用于促进本发明的剂量给药方法的试剂盒。

公开(公告)号：US20050101618A1

公开(公告)日：2005-05-12

申请号：US10982996

申请日：2004-11-04

Applicant: Richard Connell ,  Louis Denis ,  Jitesh Jani

Inventor： Richard Connell ,  Louis Denis ,  Jitesh Jani

IPC: A61K31/498 ,  A61K31/517 ,  A61K39/395 ,  A61K45/06

CPC classification number: A61K31/498 ,  A61K31/517 ,  A61K39/395 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention relates to a method of treatment of cancer with a combination of an erbB2 ligand and an antibody, in mammals. More particularly, this invention relates to a method of treating cancer by administering an erbB2 ligand in combination with an erbB antibody. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

Abstract translation: 本发明涉及哺乳动物用erbB2配体和抗体的组合治疗癌症的方法。 更具体地，本发明涉及通过与erbB抗体组合施用erbB2配体来治疗癌症的方法。 本发明还涉及可用于治疗哺乳动物，特别是人类异常细胞生长的试剂盒。

公开(公告)号：US20070197517A1

公开(公告)日：2007-08-23

申请号：US10643546

申请日：2003-08-19

Applicant: Jitesh Jani ,  Jean Beebe ,  Tracey Schaeffer ,  Diane Healey ,  Karen Ferrante ,  James O'Leary

Inventor： Jitesh Jani ,  Jean Beebe ,  Tracey Schaeffer ,  Diane Healey ,  Karen Ferrante ,  James O'Leary

IPC: A61K31/41 ,  A61K31/35 ,  A61K31/53 ,  C07D239/42

CPC classification number: A61K31/282 ,  A61K31/337 ,  A61K31/425 ,  A61K31/427 ,  A61K31/454 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7048 ,  A61K2300/00

Abstract: This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane derivative, a platinium coordination complex selected from the group consisting of carboplatin, tetraplatin, and topotecan, a nucleoside analog selected from the group consisting of gemcitabine hydrochloride and 5-FU, an anthracycline, a topoisomerase selected from the group consisting of etoposide, teniposide, amsacrine, topotecan, and Camptosar®, an aromatase inhibitor; and (ii) a therapeutically effective amount of an isothiazole derivative. The combinations of the present invention may optionally include an anti-hypertensive agent. This invention also relates to pharmaceutical compositions useful in the treatment of hyperproliferative diseases in mammals, containing such combinations. The present invention also relates to kits having a first compartment with a compound of formula 1 and a second compartment containing a taxane derivative, a platinum coordination complex, a nucleoside analog, an anthracycline, a topoisomerase inhibitor, or an aromatase inhibitor and a third compartment containing an anti-hypertensive agent.

Abstract translation: 本发明涉及一种治疗过度增殖性疾病的方法。 更具体地说，本发明涉及治疗过度增殖性疾病如癌症的方法，其包括以下步骤：同时或依次给予需要这种治疗的哺乳动物，（i）治疗有效量的紫杉烷衍生物， 选自卡铂，四铂和托泊替康的铂配位络合物，选自盐酸吉西他滨和5-FU的核苷类似物，蒽环类，拓扑异构酶，其选自依托泊苷，替尼泊苷，安吖啶， 拓扑替康和Camptosar（芳香酶抑制剂）; 和（ii）治疗有效量的异噻唑衍生物。 本发明的组合可以任选地包括抗高血压剂。 本发明还涉及可用于治疗哺乳动物中含有这种组合的过度增殖性疾病的药物组合物。 本发明还涉及具有具有式1化合物的第一隔室和含有紫杉烷衍生物，铂配位络合物，核苷类似物，蒽环类，拓扑异构酶抑制剂或芳香酶抑制剂和第三隔室的第二隔室的试剂盒 含有抗高血压药。